In conclusion, PSCC subgroups defined by the SPP1 gene have significantly different immune microenvironment and prognosis, which demonstrated that SPP1 might be a reliable prognostic and predictive biomarker of immunotherapy in patients with PSCC. The gene discussed is SPP1; the disease is squamous cell carcinoma of penis.